NovoCure, a biotechnology firm specializing in cancer treatments, is considered undervalued at a $1.66 billion market cap. The company's revenue grew 16% year-over-year to $183.58 million, driven by accelerating international sales and patient adoption, especially for new products like Optune Pax. Its valuation multiples are below industry averages, suggesting potential for growth. Upcoming product launches, including Optune Mya, and a strong balance sheet support a favorable risk-reward outlook and potential multiple expansion.
NovoCure, a biotech company, is the subject here. For readers following the health sector, Pluang data as of Oct 13, 2026 21:31 WIB shows 128 US health stocks priced, with 17 rising and 110 falling. Notable movers include NUWE at USD 0.65 with a -3.03% change and 86% sell order activity, ABEO at USD 4.75 down 2.96%, and BSX at USD 42.55 down 2.93% with 91% sell orders.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
